We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

By LabMedica International staff writers
Posted on 28 Mar 2024
Print article
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use of circulating cell-free nucleic acids found in blood. However, efficiently extracting these nucleic acids has posed a significant challenge. Now, researchers have developed an effective method for enriching trace amounts of circulating nucleic acids present in blood that could enable early disease diagnosis.

The new blood circulating nucleic acid enrichment technique developed by a research team from the Chinese Academy of Sciences (CAS, Beijing, China) is based on MOF (metal-organic framework) materials and demonstrated higher enrichment efficiency than commercial reagent kits as well as prevented RNA degradation. Furthermore, by combining this innovative technique with high-throughput sequencing and bioinformatics analysis, the team has been able to identify serum biomarkers of cell-free RNA for the non-invasive diagnosis of liver cancer. A detection model developed by the team showed that it was capable of identifying liver cancer with a diagnostic accuracy of 90% in a validation sample cohort, showcasing its potential for the non-invasive diagnosis of liver cancer.

Related Links:
Chinese Academy of Sciences

New
Gold Member
Strep Pneumoniae Rapid Test
Strep Pneumoniae (6503 – 6573)
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Syphilis Infection Test
IMPACT RPR
New
Washer Disinfector
Tiva 8

Print article

Channels

Microbiology

view channel
Image

POC PCR Test Rapidly Detects Bacterial Meningitis Directly at Point of Sample Collection

Meningitis is an inflammation of the membranes surrounding the brain and spinal cord. Pathogens typically enter the body through the respiratory tract and spread via the bloodstream. The infection can... Read more

Pathology

view channel
Image: The unique AI tool predicts cancer prognoses and responses to treatment (Photo courtesy of Shutterstock)

AI Tool Combines Data from Medical Images with Text to Predict Cancer Prognoses

The integration of visual data (such as microscopic and X-ray images, CT and MRI scans) with textual information (like exam notes and communications between doctors of different specialties) is a crucial... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The investment is in line with Danaher’s aim to accelerate the transition to precision medicine with AI-enabled diagnostics

Danaher Partners with Healthcare AI Company Innovaccer on Novel Digital and Diagnostic Solutions

Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (Washington, DC, USA), has formed an investment partnership with healthcare artificial intelligence (AI) company... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.